MOUNJARO (TIRZEPATIDE)

What makes tirzepatide different

Most weight-management injectables act on a single receptor, GLP-1. Tirzepatide is a dual agonist: it activates GIP receptors as well.

GIP is another incretin hormone released after eating. Acting on both pathways appears to improve appetite suppression and glucose handling beyond what GLP-1 alone achieves, which is reflected in the trial data.

Reported effectiveness

In published clinical trials, tirzepatide produced average total body weight reductions of roughly 20% at the highest doses over about 72 weeks, alongside lifestyle intervention.

It also produces marked improvements in blood glucose control, which is why it was first approved for type 2 diabetes before its role in weight management was established.

Who it is prescribed for

Prescribing follows the same eligibility framework as other GLP-1 medicines: a BMI of 30 or above, or 27 or above with a weight-related health condition.

It is often considered where type 2 diabetes or insulin resistance coexists with obesity, though your doctor decides based on your full clinical picture.

Dosing and the titration schedule

Treatment starts at a low weekly dose and increases in steps at scheduled reviews. The pace is deliberately slow, because tolerance improves markedly when the body is given time to adapt.

Doses are never adjusted without medical review. Self-escalating is the most common cause of avoidable side effects.

Side effects to expect

Nausea, reduced appetite, constipation or loose stools, and occasional reflux are the most commonly reported effects. They are typically strongest in the days after a dose increase and settle with time.

Rarer but more serious effects, including pancreatitis and gallbladder problems, are discussed with you before you start so you know which symptoms warrant immediate contact.

Who should not take it

It is not prescribed where there is a personal or family history of medullary thyroid carcinoma or MEN2 syndrome, in pregnancy or while breastfeeding, or where there is a history of pancreatitis.

Your doctor will also review all current medications, as some require adjustment when a GLP-1 medicine is added.

What GIP adds

GIP, or glucose-dependent insulinotropic polypeptide, is the other major incretin hormone. For years its role in weight regulation was debated, because GIP receptor activation had appeared to promote fat storage in some models.

In practice, combining GIP with GLP-1 activation produces greater weight reduction than GLP-1 alone. The prevailing explanation is that GIP contributes additional effects on appetite signalling in the brain and improves how the body handles fat and glucose.

What monitoring looks like

Reviews are scheduled around dose increases rather than at arbitrary intervals. Each covers weight trend, waist measurement, side effect tolerance, nutritional intake and any new symptoms.

Blood work is repeated periodically to track glucose control, liver function and nutritional markers. If you have diabetes, existing medication frequently needs adjusting as control improves, which is a clinical decision rather than something to manage alone.

Storage and handling

Pens require refrigeration within a specified temperature range and must not be frozen. Once removed, there is a limited window in which the pen remains usable at room temperature.

Your team will cover storage, travel, needle disposal in a sharps container and what to do if the cold chain is broken. Getting this wrong can render the medicine ineffective.

How tirzepatide compares with GLP-1-only medicines

Semaglutide acts on the GLP-1 receptor alone. Tirzepatide adds GIP receptor activity, and the trial data reflect that difference: average weight reductions of roughly 20% at the highest tirzepatide doses versus roughly 15% for high-dose semaglutide.

That gap is meaningful at a population level but does not predict any individual's result. A patient who tolerates semaglutide well may do better on it than on a tirzepatide dose they cannot reach.

Side effect profiles are broadly similar, since the mechanism overlaps substantially.

Switching between them is a recognised clinical option where response or tolerance is poor, and is a decision for your doctor rather than a matter of preference.

What the first six months typically look like

Month one is titration at the starting dose, with appetite change noticeable but weight change modest. Months two and three usually establish a visible downward trend as doses step up.

Months four to six are typically the steadiest period, with most patients at or near their effective dose and metabolic markers improving alongside weight.

Beyond that, weight loss slows as body mass falls. This is expected adaptation rather than the medicine ceasing to work.

Patients who judge treatment on month one and stop almost always do so before reaching a dose that would have worked.

Practical questions to ask before starting

What dose do you expect I will need, and what will that cost per month at that strength? What is included beyond the medicine itself?

How often will you review me, what will you check, and who do I contact if something concerns me outside clinic hours?

What happens if I do not tolerate it — will you hold the dose, reduce it, or consider switching? What is the plan for stopping, and when will we discuss it?

A clinician who answers these clearly is giving you what you need to decide. One who deflects is telling you something too.

Frequently asked questions